Affiliation:
1. Wilmer Eye Institute, Johns Hopkins University School of Medicine
2. Department of Oncology, Johns Hopkins University School of Medicine
3. Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine
Abstract
Abstract
Purpose
To describe tumor response and cranial nerve function outcomes after administration of anti-PD-1 to patients with cutaneous squamous cell carcinoma (CSCC) with perineural spread to cranial nerves (CN) extending into the cavernous sinus.
Methods
Electronic patient records from a single institution were queried for patients with CSCC of the head and neck causing diplopia (ICD-10 H53.2) who were treated with anti-PD-1. Data extracted included demographics, duration of anti-PD-1 therapy, immune-mediated adverse reactions, tumor response per adapted RECIST v1.1, and changes in CN function and symptoms (e.g., pain). All patients were prescribed cemiplimab 350 mg IV q3 weeks.
Results
Four patients met inclusion criteria. They had varying degrees of pain and sensory deficits in branches of the trigeminal nerve (CN V). One, 2, 3 and 1 patients had baseline involvement of CN III, IV, VI and VII, respectively. MRI confirmed perineural cavernous sinus involvement in all patients. Duration of anti-PD-1 therapy ranged 15–60 weeks. All patients experienced an objective anti-tumor response to anti-PD-1; partial response n = 2, complete response n = 2. At a median follow-up of 22 months, responses were ongoing in all patients. All patients demonstrated improvement in ocular motility deficits and pain with resolution of symptoms in 3 and 1 patients, respectively.
Conclusion
Administration of anti-PD-1 to patients with CSCC with perineural spread into the cavernous sinus can generate durable anti-tumor regressions and restore CN function, while sparing the morbidity associated with surgical resection and/or radiotherapy. Our findings add to emerging literature supporting this treatment approach for this patient population.
Publisher
Research Square Platform LLC
Reference15 articles.
1. Insight on common forms of cutaneous head and neck carcinoma (Review);Iancu DC-E;Mol Clin Oncol,2023
2. Occult perineural tumor infiltration of the trigeminal nerve. Diagnostic considerations;Hove MW;J Neuroophthalmol,1997
3. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma;Migden MR;N Engl J Med,2018
4. Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629);Grob J-J;J Clin Oncol,2020
5. Center for Drug Evaluation, Research FDA approves cemiplimab-rwlc for metastatic or locally advanced cutaneous squamous cell carcinoma. In: U.S. Food and Drug Administration. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-cemiplimab-rwlc-metastatic-or-locally-advanced-cutaneous-squamous-cell-carcinoma. Accessed 30 Apr 2023